Risk of Conducting Long-Term, Large-Scale Hepatitis-Related Clinical Trials
First written in FY2016. 3 of 4 entries say "Restated". Latest entry: FY2020.
No other company in this theme has enough history to compare yet.
- FY2020RestatedAnnual report
「Because hepatitis-related studies among the contract research services are conducted over an extended period, they may be large-scale studies accounting for more than 5% of total sales.」
The risk that delays or unforeseen problems in long-term, large-scale hepatitis-related studies could affect performance is being reassessed. - FY2018RestatedAnnual report
「Because hepatitis-related studies among the contract research services are conducted over an extended period, they may be large-scale studies accounting for more than 5% of total sales.」
The risk that delays or unforeseen problems in long-term, large-scale hepatitis-related studies could affect performance is being reassessed. - FY2017RestatedAnnual report
「Because hepatitis-related studies among the contract research services are conducted over an extended period, they may be large-scale studies accounting for more than 5% of total sales.」
The risks of delays and problems associated with long-term, large-scale hepatitis-related studies are disclosed again. - FY2016First statedAnnual report
「Because hepatitis-related studies among the contract research services are conducted over an extended period, they may be large-scale studies accounting for more than 5% of total sales.」
The disclosure links the potential impact of study delays and unforeseen problems on performance to studies exceeding 5% of total sales.